NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

ICICI Lombard Posts Strong Earnings Growth Amid Sectoral Challenges

ICICI Lombard General Insurance Company has reported a healthy earnings compound annual growth rate (CAGR) of 17% over the last three years and 15% over the last six years. This highlights the compounding potential of the stock, making it an attractive investment opportunity.

The company's performance has improved despite sectoral challenges, such as lower motor growth and higher loss ratios. However, growth has picked up, and the outlook remains positive amidst heightened industry loss ratios and the possibility of a motor third-party (TP) hike. Additionally, the company's increasing market share in the health segment and improving return on equity (RoE) are expected to contribute incrementally to its growth.

Maintaining a Positive Outlook

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

ICICI Securities maintains a BUY recommendation for ICICI Lombard with an unchanged target price (TP) of INR 2,250. This target price is based on a 30x multiple of the company's estimated earnings per share (EPS) for fiscal year 2028 (FY28E), which is INR 75. This represents an increase in multiple from 28x FY28E EPS of INR 79.4, reflecting a better underwriting outlook. The decrease in earnings is due to lower investment leverage as of FY26 end.

| Recommendation Comparison |

MultipleFY28E EPSTarget Price
30xINR 75INR 2,250
28xINR 79.4(Previous Target Price)

The research report provides a comprehensive analysis of ICICI Lombard's performance and outlook, making it an essential read for investors and analysts interested in the insurance sector.

Investor Takeaway

Maintain BUY with an unchanged TP of INR 2,250, based on 30x FY28E EPS of INR 75.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.